News

Ventavis and Nitric Oxide Both Seen to Treat Hypertension in CTEPH Patients After Surgery

Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two treatments — published in the journal General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study…

Faster Administration of Remodulin May Help to Ease Infusion Site Pain in PAH Patients, Study Says

Although subcutaneous infusion of Remodulin (treprostinil) is an effective treatment for patients with severe pulmonary arterial hypertension (PAH), it can have undesired effects such as pain at the infusion site. But a study reports that speeding up Remodulin administration, and combining it with injection-site pain management, is an easily tolerated option that may help patients better…

Investigative Treatment for Pulmonary Arterial Hypertension Fails to Meet Top Goal in Phase 2 Study

Gilead Sciences reported that selonsertib (also known as GS-4997), an investigational treatment for pulmonary arterial hypertension (PAH), did not achieve the primary endpoint in an analysis of ARROW, a Phase 2 clinical trial (NCT02234141) evaluating the drug’s efficacy, safety and tolerability. The company also reported top-line data from two other…

#CHEST2016 – Bayer to Share New Data on Adempas for PAH at Meeting

Bayer will present new data from two different studies of Adempas (riociguat) for pulmonary arterial hypertension (PAH) at the American College of Chest Physicians (CHEST) 2016 Annual Meeting Oct. 22-26 in Los Angeles. One of the presentations will be held during the Late-Breaking Abstracts session of the meeting. Bayer will also…

PHA Puts Special Focus on CTEPH for Pulmonary Hypertension Awareness Month

The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…

S1P Molecule Seen to Promote PAH, May Offer New Way of Treating Disease

Patients with pulmonary arterial hypertension (PAH) have higher than usual blood levels of S1P, a molecule that promotes worsening disease, according to a study published in the journal Pulmonary Circulation. The researchers, working in a rat PAH model, also found that blocking this protein improved pulmonary arterial structure and cardiac function, suggesting…

Inhaled Tyvaso for PAH is Safe, Well Tolerated by Patients, Study Shows

Tyvaso (treprostinil sodium), a drug approved for enhancing exercise capacity in patients with pulmonary arterial hypertension (PAH), was reported in a recent study to be well tolerated and safe in routine clinical use. The study, “An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension,” was published…

Elsevier to Create eLearning Programs for PAH and Other Respiratory Specialists

Elsevier  announced that it is expanding its work with the American College of Chest Physicians (CHEST) to provide CHEST members with detailed and interactive eLearning programs that address their specialities, including pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Elsevier is a provider of scientific, technical and medical information products, and the…